Gencurix (229000) Fundamentals 2026 — Revenue Analysis | SniperIQ
Gencurix (229000) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩24.4B, trading at ₩1598.00 on the KOE. This SniperIQ fundamentals page covers Gencurix's valuation, profitability (net margin -97.7%), revenue (₩7.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Gencurix's market cap?
Gencurix (229000) has a market capitalization of approximately ₩24.4B, trading at ₩1598.00 on the KOE. Market cap moves with the live share price.
What is Gencurix's P/E ratio?
Gencurix's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Gencurix?
Gencurix runs a net profit margin of -97.7%, a gross margin of 76.5%, and an operating margin of -90.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Gencurix generate?
Gencurix reported revenue of ₩7.5B for fiscal year 2025, with net income of -₩7.4B and earnings per share (EPS) of -462.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Gencurix pay a dividend?
Gencurix does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Gencurix financially healthy?
Gencurix carries a debt-to-equity ratio of 0.76x and a current ratio of 0.56x, with a market beta of 1.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Gencurix a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Gencurix (229000) the key facts are: market cap ₩24.4B, revenue ₩7.5B, 52-week range 1385-7320. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Gencurix's full fundamentals live
Get Gencurix's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.